FDA Sends Warning Letters to CIs for Deviating from Protocols

Clinical Trials Advisor
A A
The FDA has issued warning letters to two clinical investigators who deviated from their investigational plans.

To View This Article:

Login

Subscribe To Clinical Trials Advisor